Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114803 · ClinicalTrials.gov registry record · NA
Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease
A NA study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT00114803 is a NA study that has completed, run by Boston Children's Hospital. The registered enrollment target is 66 participants.
The verdict
NCT00114803, a NA study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The hypothesis underlying this study is that nasally administered calcitonin will stabilize or improve bone mineral density in young patients with ulcerative colitis or Crohn's disease. Patients who participate will receive either calcitonin or placebo and will have their bone mineral density measured at the start, at nine months, and at 18 months of study. Participants will also receive age appropriate doses of vitamin D and calcium supplements. Other serological measures of vitamin D status will be obtained every 3 months during the study.
Interventions
- DRUG Calcitonin nasal spray (salmon)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114803
The ClinicalTrials.gov registry entry for NCT00114803 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calcitonin nasal spray (salmon) is the first listed.
NCT00114803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114803 about?
NCT00114803 is a clinical study titled "Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease". The hypothesis underlying this study is that nasally administered calcitonin will stabilize or improve bone mineral density in young patients with ulcerative colitis or Crohn's disease. Patients who participate will receive either calcitonin or placebo and will have their bone mineral density measur...
What is the current status of trial NCT00114803?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2004-01. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00114803?
The interventions under investigation include: Calcitonin nasal spray (salmon) (DRUG).
Who is sponsoring clinical trial NCT00114803?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.